162 related articles for article (PubMed ID: 23429449)
1. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
Sakuraba A; Keyashian K; Correia C; Melek J; Cohen RD; Hanauer SB; Rubin DT
Inflamm Bowel Dis; 2013 Mar; 19(3):621-6. PubMed ID: 23429449
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.
Juillerat P; Wasan SK; Fowler SA; Friedman S; Pabby VK; Coukas JA; Barto AE; Pellish R; Germansky KA; Cheifetz AS; Korzenik JR; Farraye FA; Yajnik V
Inflamm Bowel Dis; 2013 Oct; 19(11):2457-63. PubMed ID: 23962896
[TBL] [Abstract][Full Text] [Related]
3. Real World Experience With Natalizumab at a Tertiary Care Pediatric IBD Center.
Singh N; Deshpande R; Rabizadeh S; Dubinsky M
J Pediatr Gastroenterol Nutr; 2016 Jun; 62(6):863-6. PubMed ID: 27213249
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
Bellaguarda E; Keyashian K; Pekow J; Rubin DT; Cohen RD; Sakuraba A
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1919-25. PubMed ID: 26001336
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience.
Kane SV; Horst S; Sandborn WJ; Becker B; Neis B; Moscandrew M; Hanson KA; Tremaine WJ; Bruining DH; Faubion WA; Pardi DS; Harmsen WS; Zinsmeister AR; Loftus EV
Inflamm Bowel Dis; 2012 Dec; 18(12):2203-8. PubMed ID: 22419661
[TBL] [Abstract][Full Text] [Related]
9. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.
Sakuraba A; Annunziata ML; Cohen RD; Hanauer SB; Rubin DT
Inflamm Bowel Dis; 2013 Nov; 19(12):2577-83. PubMed ID: 24132161
[TBL] [Abstract][Full Text] [Related]
10. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
11. Crohn's targeted therapy: myth or real goal?
Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K
Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597
[TBL] [Abstract][Full Text] [Related]
12. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
[TBL] [Abstract][Full Text] [Related]
14. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
[TBL] [Abstract][Full Text] [Related]
15. [Natalizumab for the treatment of Crohns disease: Report of three cases].
Fluxá D; Ibáñez P; Flores L; Figueroa C; Lubascher J; Kronberg U; Simian D; Pizarro G; Toche P; Quera R
Rev Med Chil; 2017 Apr; 145(4):538-543. PubMed ID: 28749002
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
[TBL] [Abstract][Full Text] [Related]
19. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic features of Crohn's disease associated with failure of medical treatment.
Moran GW; Dubeau MF; Kaplan GG; Yang H; Seow CH; Fedorak RN; Dieleman LA; Barkema HW; Ghosh S; Panaccione R;
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
